MLB sues Biogeneis, Anthony Bosch, claims interference with contract

57 Comments

Major League Baseball has filed its lawsuit against Anthony Bosch and Biogenesis. There are multiple other defendants as well.* The claim: that by selling drugs to major league players, Biogenesis and Anthony Bosch “enabled such Players to possess and/or use [performance enhancing drugs] and thus knowingly and intentionally caused and/or induced such Players to breach their contractual obligations under MLB’s Joint Drug Prevention and Treatment Program not to possess or use [performance enhancing drugs].”

UPDATE: The entire complaint can be seen below.

This morning my primary legal criticism of the claims were that Major League Baseball could not show damages as a result of these acts. I have not changed my mind, if for no other reason than the contract MLB claims interference with is the Joint Drug Agreement, in which MLB has no direct financial interest. Indeed, it EXPECTS the JDA to be breached and has built in a punishment system because of it. When a player takes PEDs he violates it, by definition. Major League Baseball does not have a cause of action for breach of contract against them. How Major League Baseball expects to get greater satisfaction from an alleged third party tortfeasor than it could get from a party to the contract is … interesting.

That said, here are their damages allegations:

Due to Defendants’ actions, MLB has suffered damages, including the costs of investigation, loss of goodwill, loss of revenue and profits and injury to its reputation, image, strategic advantage and fan relationships.

Nothing surprising. But also nothing which seems at all to be the stuff of a meritorious lawsuit.  It’s loss of goodwill, outside of that involving a few columnists, is impossible to quantify. Its revenue and profits are at record highs and many would argue that these were achieved thanks in part to the PED-inflated offensive numbers of the past 20 years, not despite it.

This lawsuit is crazy on its face. It should be thrown out of court. I am shocked Major League Baseball found someone who would file it.

source:

source:

source:

source:

source:

source:

source:

source:

source:

source:

source:

source:

source:


source:

*The defendants:  BioGenesis of America, LLC, a Florida Limited Liability Company (“BioGenesis”); Biokem, LLC, a Florida Limited Liability Company (“Biokem”); Anthony P. Bosch (“Bosch”); Carlos Acevedo (“Acevedo”); Ricardo J. Martinez (“Martinez”); Juan Carlos Nunez (“Nunez”); Marcelo Albir (“Albir”); and Paulo da Silveira

Rangers don’t plan to make qualifying offer to Adrián Beltré

Ronald Martinez/Getty Images
3 Comments

Rangers GM Jon Daniels said he doesn’t expect the club to make a $17.9 million qualifying offer to free agent third baseman Adrián Beltré, MLB.com’s T.R. Sullivan reports. Daniels has been in touch with the 39-year-old, who may retire.

Beltré battled hip and hamstring issues throughout the past season, limiting him to 119 games. He hit .273/.328/.434 with 15 home runs and 65 RBI in 481 plate appearances. Going by adjusted OPS, his mark of 98 — 100 is average — was his lowest in a season since 2009 with the Mariners. Beltré’s career average is 116 and he put up a 132 in 2017 and 128 in ’16.

Beltré appears to have some stuff left in the tank. He may not be an All-Star-caliber player anymore, but he can still hit at an average level and he is still an above-average defender. It’s just a matter of his body holding up to allow him to do what he needs to do. If Beltré does decide to re-up with the Rangers for 2019, the club will be prepared to move Isiah Kiner-Falefa or Jurickson Profar over to the hot corner as they did in 2018 in the event Beltré gets bitten by the injury bug.